Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 6,880,000 shares, a growth of 19.4% from the January 15th total of 5,760,000 shares. Based on an average daily trading volume, of 2,010,000 shares, the short-interest ratio is presently 3.4 days.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. raised its holdings in Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after acquiring an additional 1,626,657 shares during the period. Jane Street Group LLC raised its holdings in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 98,581 shares during the period. GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at $95,000. Virtu Financial LLC grew its position in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares in the last quarter. Finally, FMR LLC grew its position in shares of Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 50,419 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Up 0.3 %

Shares of ADAP stock opened at $0.58 on Friday. The company’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $0.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a 1 year low of $0.53 and a 1 year high of $2.05. The stock has a market capitalization of $147.90 million, a price-to-earnings ratio of -2.63 and a beta of 2.42.

Wall Street Analyst Weigh In

ADAP has been the topic of a number of research reports. StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. HC Wainwright lowered their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Guggenheim lowered their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Mizuho lowered their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Adaptimmune Therapeutics has a consensus rating of “Buy” and a consensus price target of $2.79.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.